KRAS and colorectal cancer: Without having the detailed information about the complex structure of the nanocarriers presented here, we have used this system [3–5] using the epidermal growth factor receptor (EGFR) antibody cetuximab to target EGFR-positive colorectal cancer cells and inhibit their growth by RNAi against their major targets KRAS and PIK3CA.